[go: up one dir, main page]

AU2001268040A1 - Methods and compounds for inhibiting mrp1 - Google Patents

Methods and compounds for inhibiting mrp1

Info

Publication number
AU2001268040A1
AU2001268040A1 AU2001268040A AU6804001A AU2001268040A1 AU 2001268040 A1 AU2001268040 A1 AU 2001268040A1 AU 2001268040 A AU2001268040 A AU 2001268040A AU 6804001 A AU6804001 A AU 6804001A AU 2001268040 A1 AU2001268040 A1 AU 2001268040A1
Authority
AU
Australia
Prior art keywords
compounds
methods
inhibiting mrp1
mrp1
inhibiting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001268040A
Inventor
Rosanne Bonjouklian
Jeremy Schulenburg York
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of AU2001268040A1 publication Critical patent/AU2001268040A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20Oxygen atoms
    • C07D215/22Oxygen atoms attached in position 2 or 4
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2001268040A 2000-06-23 2001-06-12 Methods and compounds for inhibiting mrp1 Abandoned AU2001268040A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21338000P 2000-06-23 2000-06-23
US60213380 2000-06-23
PCT/US2001/010849 WO2002000624A2 (en) 2000-06-23 2001-06-12 Methods and compounds for inhibiting mrp1

Publications (1)

Publication Number Publication Date
AU2001268040A1 true AU2001268040A1 (en) 2002-01-08

Family

ID=22794896

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001268040A Abandoned AU2001268040A1 (en) 2000-06-23 2001-06-12 Methods and compounds for inhibiting mrp1

Country Status (5)

Country Link
US (1) US6686376B2 (en)
EP (1) EP1296953A2 (en)
AU (1) AU2001268040A1 (en)
CA (1) CA2413579A1 (en)
WO (1) WO2002000624A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1281210C (en) * 2003-11-29 2006-10-25 胡汛 Application of Schisandrin-B in preparing medicine for treating tumor
TWI287599B (en) * 2006-04-21 2007-10-01 Miz Engineering Ltd Multifunctional safety lock for computer
BR112014032538A2 (en) 2012-06-26 2017-06-27 Bayer Pharma AG n- [4- (quinolin-4-yloxy) cyclohexyl (methyl)] (hetero) arylcarboxamides as androgen receptor antagonists, production and use thereof as medicinal products
UY36391A (en) * 2014-11-05 2016-06-01 Flexus Biosciences Inc MODULATING COMPOUNDS OF INDOLAMINE ENZYME 2,3-DIOXYGENASE (IDO1), ITS SYNTHESIS METHODS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
AU2019232437A1 (en) 2018-03-07 2020-10-08 Bayer Aktiengesellschaft Identification and use of ERK5 inhibitors
EP3972963A1 (en) 2019-05-21 2022-03-30 Bayer Aktiengesellschaft Identification and use of kras inhibitors

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999051227A1 (en) * 1998-04-08 1999-10-14 Eli Lilly And Company Methods for inhibiting mrp1
ES2233487T3 (en) 1999-12-22 2005-06-16 Eli Lilly And Company PROCEDURES AND COMPOUNDS FOR THE INHIBITION OF MRP1.

Also Published As

Publication number Publication date
WO2002000624A3 (en) 2002-04-18
US6686376B2 (en) 2004-02-03
EP1296953A2 (en) 2003-04-02
US20030232854A1 (en) 2003-12-18
CA2413579A1 (en) 2002-01-03
WO2002000624A2 (en) 2002-01-03

Similar Documents

Publication Publication Date Title
AU2001258771A1 (en) -secretase inhibitors
AU2002225730A1 (en) Compounds
AU2001286243A1 (en) Tetrahydroquinoline compounds
AU2001280599A1 (en) Compounds and methods
AU2001253418A1 (en) Compounds and methods
AUPQ661800A0 (en) Insulin-potentiating compounds
AU2001239765A1 (en) Novel compounds
AU2001246998A1 (en) Novel compounds
AU2001243394A1 (en) Compounds and methods
AU2001253362A1 (en) Novel compounds
AU2001220281A1 (en) Rollerboard for road-skiing
AU2001258841A1 (en) Heterocyclic compounds
AUPQ872300A0 (en) Compounds and methods
AU2001256964A1 (en) Novel compounds
AU2002225724A1 (en) Motilide compounds
IL138389A0 (en) Methods for inhibiting mrp1
AU2001266176A1 (en) Methods
AU2001278951A1 (en) Compounds and methods
AU2002217285A1 (en) Compounds
AU2001268040A1 (en) Methods and compounds for inhibiting mrp1
IL138391A0 (en) Methods for inhibiting mrp1
AU2001230689A1 (en) Novel compounds
PL343320A1 (en) Methods for inhibiting mrp1
AU2002235277A1 (en) Compounds and methods
AU2001250536A1 (en) Methods